Pharmacokinetic evaluation of vadimezan (ASA404, 5,6-dimethylxanthenone-4-acetic acid, DMXAA)

Bibliography

• Denekamp J. Vascular endothelium as the vulnerable element in tumours. Acta Radiol Oncol 1984;7:217-25
   Google Scholar
• Konerding MA, Malkusch W, Klapthor B, Evidence for characteristic vascular patterns in solid tumours: quantitative studies using corrosion casts. Br J Cancer 1999;80:724-32
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6
   PubMed Web of Science ®Google Scholar
• Siemann DW, Chaplin DJ, Horsman MR. Vascular-targeting therapies for treatment of malignant disease. Cancer 2004;100:2491-9
   PubMed Web of Science ®Google Scholar
• Lippert JW III. Vascular disrupting agents. Bioorg Med Chem 2007;15:605-15
   PubMed Web of Science ®Google Scholar
• Ching LM, Zwain S, Baguley BC. Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice. Br J Cancer 2004;90:906-10
   PubMed Web of Science ®Google Scholar
• Kestell P, Zhao L, Jameson MB, Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents. Clin Chim Acta 2001;314:159-66
   PubMed Web of Science ®Google Scholar
• Kelland LR, Baguley BC, Zhao L, Plasma levels of 5-hydroxyindole-3-acetic acid (5HIAA) as a pharmacodynamic marker of blood flow changes induced by the vascular targeting agent (VTA) 5,6 dimethyl xanthenone acetic acid, DMXAA. Proc Annu Meet Am Soc Clin Oncol 2005;24:#3123
   Google Scholar
• Baguley BC, Siemann DW. Temporal aspects of the action of ASA404 (vadimezan; DMXAA). Expert Opin Investig Drugs 2010;19:1413-25
   PubMed Web of Science ®Google Scholar
• Siim BG, Lee AE, Shalal-Zwain S, Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol 2003;51:43-52
   PubMed Web of Science ®Google Scholar
• Wilson WR, Li AE, Cowan DS, Siim BG. Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Int J Radiat Oncol Biol Phys 1998;42:905-8
   PubMed Web of Science ®Google Scholar
• Murata R, Siemann DW, Overgaard J, Horsman MR. Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid. Radiat Res 2001;156:503-9
   PubMed Web of Science ®Google Scholar
• Webster LK, Ellis AG, Kestell P, Rewcastle GW. Metabolism and elimination of 5,6-dimethylxanthenone-4-acetic acid in the isolated perfused rat liver. Drug Metab Dispos 1995;23:363-8
   PubMed Web of Science ®Google Scholar
• Miners JO, Valente L, Lillywhite KJ, Preclinical prediction of factors influencing the elimination of 5,6-dimethylxanthenone-4-acetic acid, a new anticancer drug. Cancer Res 1997;57:284-9
   PubMed Web of Science ®Google Scholar
• Zhou S, Kestell P, Baguley BC, Paxton JW. Preclinical factors influencing the relative contributions of Phase I and II enzymes to the metabolism of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. Biochem Pharmacol 2003;65:109-20
   PubMed Web of Science ®Google Scholar
• Zhou SF, Tingle MD, Kestell P, Paxton JW. Species differences in the metabolism of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in vitro: implications for prediction of metabolic interactions in vivo. Xenobiotica 2002;32:87-107
   PubMed Web of Science ®Google Scholar
• Zhou S, Chin R, Kestell P, Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes. Br J Clin Pharmacol 2001;52:129-36
   PubMed Web of Science ®Google Scholar
• Zhao L, Kestell P, Philpott M, Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol 2001;47:491-7
   PubMed Web of Science ®Google Scholar
• Kestell P, Zhao L, Baguley BC, Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide. Cancer Chemother Pharmacol 2000;46:135-41
   PubMed Web of Science ®Google Scholar
• Zhou S, Paxton JW, Kestell P, Tingle MD. Reversible binding of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid to plasma proteins and its distribution into blood cells in various species. J Pharm Pharmacol 2001;53:463-71
   PubMed Web of Science ®Google Scholar
• Baguley B, Jameson M, Zhao L, Implications of the albumin binding properties of the anticancer drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA) to its clinical trial. Proc Aust Soc Clin Exp Pharmacol Toxicol 1998;5:208
   Google Scholar
• Zhou S, Paxton JW, Tingle MD, Kestell P. Determination of the covalent adducts of the novel anti-cancer agent 5,6-dimethylxanthenone-4-acetic acid in biological samples by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 2001;757:343-8
   PubMedGoogle Scholar
• McKeage MJ, Kestell P, Denny WA, Baguley BC. Plasma pharmacokinetics of the antitumour agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in mice. Cancer Chemother Pharmacol 1991;28:409-13
   PubMed Web of Science ®Google Scholar
• Kestell P, Paxton JW, Rewcastle GW, Plasma disposition, metabolism and excretion of the experimental antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the mouse, rat and rabbit. Cancer Chemother Pharmacol 1999;43:323-30
   PubMed Web of Science ®Google Scholar
• Cao Z, Joseph WR, Browne WL, Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 1999;80:716-23
   PubMed Web of Science ®Google Scholar
• Jameson MB, Thompson PI, Baguley BC, Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer 2003;88:1844-50
   PubMed Web of Science ®Google Scholar
• Rustin GJ, Bradley C, Galbraith S, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study. Br J Cancer 2003;88:1160-7
   PubMed Web of Science ®Google Scholar
• Galbraith SM, Rustin GJ, Lodge MA, Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 2002;20:3826-40
   PubMed Web of Science ®Google Scholar
• McKeage MJ, Fong P, Jeffery M, 5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent. Clin Cancer Res 2006;12:1776-84
   PubMed Web of Science ®Google Scholar
• Jameson MB, Sharp DM, Sissingh JI, Transient retinal effects of 5,6-dimethylxanthenone-4-acetic acid (DMXAA, ASA404), an antitumor vascular-disrupting agent in phase I clinical trials. Invest Ophthalmol Vis Sci 2009;50:2553-9
   PubMed Web of Science ®Google Scholar
• Head M, Jameson MB. The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities. Expert Opin Investig Drugs 2010;19:295-304
   PubMed Web of Science ®Google Scholar
• McKeage MJ, Von Pawel J, Reck M, Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer 2008;99:2006-12
   PubMed Web of Science ®Google Scholar
• McKeage MJ, Reck M, Jameson MB, Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800 mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Lung Cancer 2009;65:192-7
   PubMed Web of Science ®Google Scholar
• McKeage MJ, Jameson MB; AS1404-201 Study Group Investigators. Comparative outcomes of squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of ASA404 (DMXAA) – retrospective analysis of pooled data. J Thorac Dis 2010;2:199-204
   Google Scholar
• Hida T, Tamiya M, Nishio M, Phase I study of intravenous ASA404 (vadimezan) administered in combination with paclitaxel and carboplatin in Japanese patients with non-small cell lung cancer. Cancer Sci 2011;102:845-51
   PubMed Web of Science ®Google Scholar
• CASA404A1102. A safety, tolerability study of intravenous ASA404 administered in combination with docetaxel in Japanese patients with advanced or recurrent solid tumors. Novartis Clinical Trial Results Database 2010. Available from: www.novctrd.com/ctrdWebApp/clinicaltrialrepository/public/product.jsp?divisionId=2&productID=377&diseaseAreaID=1 [Last accessed 3 April 2011]
   Google Scholar
• Gabra H; AS1404-202 Study Group Investigators. Phase II study of DMXAA combined with carboplatin and paclitaxel in recurrent ovarian cancer. J Clin Oncol 2006;24(20 Suppl):abstract 5032
   Google Scholar
• Gabra H, Jameson M. AS1404-202 Study Group Investigators. Update on randomised phase II study of DMXAA (ASA404) combined with carboplatin and paclitaxel in recurrent ovarian cancer. ECCO 14. 2007. Barcelona, Spain. 20-9-2007
   Google Scholar
• Pili R, Rosenthal MA, Mainwaring PN, Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC. Clin Cancer Res 2010;16:2906-14
   PubMed Web of Science ®Google Scholar
• Lara PN Jr, Douillard JY, Nakagawa K, Randomized Phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol 2011; published online on June 27, 2011; DOI:10.1200/JCO.2011.35.0660:
   Google Scholar
• Sandler A, Gray R, Perry MC, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50
   PubMed Web of Science ®Google Scholar
• Available from: www.antisoma.com/asm/media/press/pr2010/2010-11-11/. Antisoma.com 2010
   Google Scholar
• Jameson MB, Baguley BC, Kestell P, Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial. Cancer Chemother Pharmacol 2007;59:681-7
   PubMed Web of Science ®Google Scholar
• Rosing H, Lustig V, van Warmerdam LJ, Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion. Cancer Chemother Pharmacol 2000;45:213-18
   PubMed Web of Science ®Google Scholar
• Zhao L, Ching LM, Kestell P, Baguley BC. Improvement of the antitumor activity of intraperitoneally and orally administered 5,6-dimethylxanthenone-4-acetic acid by optimal scheduling. Clin Cancer Res 2003;9:6545-50
   PubMed Web of Science ®Google Scholar
• Zhou S, Kestell P, Tingle MD, A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide. Cancer Chemother Pharmacol 2001;47:541-4
   PubMed Web of Science ®Google Scholar
• Chung F, Palmer BD, Muller GW, Effect of 3-fluorothalidomide and 3-methylthalidomide enantiomers on tumor necrosis factor production and antitumor responses to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Oncol Res 2003;14:75-82
   PubMed Web of Science ®Google Scholar
• Chung F, Liu J, Ching LM, Baguley BC. Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide. Cancer Chemother Pharmacol 2008;61:497-502
   PubMed Web of Science ®Google Scholar
• Ching LM, Browne WL, Tchernegovski R, Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the antitumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of antitumour activity. Br J Cancer 1998;78:336-43
   PubMed Web of Science ®Google Scholar
• Wang LC, Ching LM, Paxton JW, Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) by non-steroidal anti-inflammatory drugs. Invest New Drugs 2009;27:280-4
   PubMed Web of Science ®Google Scholar
• Baguley BC, Zhan X, Finlay GJ. The antitumor action of ASA404 (vadimezan; DMXAA); potential involvement of vascular endothelial growth factor (VEGF). Proc Annu Meet Am Assoc Cancer Res 2010;101:#1660
   Google Scholar
• Djeha H, Green C, Ireson C, Kelland LR. Synergistic in vivo antitumor activity in lung and colon cancer xenografts with the vascular disrupting agent DMXAA combined with bevacizumab. Proc Annu Meet Am Assoc Cancer Res 2006;2006:#233
   Google Scholar
• Ching LM, Joseph WR, Baguley BC. Stimulation of macrophage tumouricidal activity by 5,6-dimethyl-xanthenone-4-acetic acid, a potent analogue of the antitumour agent flavone-8-acetic acid. Biochem Pharmacol 1992;44:192-5
   PubMed Web of Science ®Google Scholar
• Zhou S, Feng X, Kestell P, Transport of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide by human intestinal Caco-2 cells. Eur J Pharm Sci 2005;24:513-24
   PubMed Web of Science ®Google Scholar
• Bellnier DA, Gollnick SO, Camacho SH, Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors. Cancer Res 2003;63:7584-90
   PubMed Web of Science ®Google Scholar
• Marrero A, Becker T, Sunar U, Aminolevulinic acid-photodynamic therapy combined with topically applied vascular disrupting agent vadimezan leads to enhanced antitumor responses. Photochem Photobiol 2011; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Seshadri M, Bellnier DA. The vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid improves the antitumor efficacy and shortens treatment time associated with Photochlor-sensitized photodynamic therapy in vivo. Photochem Photobiol 2009;85:50-6
   PubMed Web of Science ®Google Scholar
• Shirey KA, Nhu QM, Yim KC, The anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), induces IFN-{beta}-mediated antiviral activity in vitro and in vivo. J Leukoc Biol 2011;89:351-7
   PubMed Web of Science ®Google Scholar